Background: Accurately characterizing a drug’s safety profile is essential Trial harm and tolerability assessments rely  in part  on participants’ reports of medical histories  adverse events (AEs)  and concomitant medications Optimal methods for questioning participants are unclear  but different methods giving different results can undermine meta-analyses